Equities research analysts expect Theravance Biopharma, Inc. (NASDAQ:TBPH) to announce earnings per share of ($1.14) for the current quarter, Zacks reports. Two analysts have made estimates for Theravance Biopharma’s earnings, with the highest EPS estimate coming in at ($1.09) and the lowest estimate coming in at ($1.19). Theravance Biopharma reported earnings per share of ($0.73) in the same quarter last year, which would indicate a negative year-over-year growth rate of 56.2%. The business is expected to announce its next earnings results on Tuesday, November 14th.

On average, analysts expect that Theravance Biopharma will report full year earnings of ($4.56) per share for the current fiscal year, with EPS estimates ranging from ($4.90) to ($4.34). For the next financial year, analysts forecast that the business will report earnings of ($3.85) per share, with EPS estimates ranging from ($4.01) to ($3.70). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Theravance Biopharma.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.14) by $0.13. Theravance Biopharma had a negative net margin of 641.67% and a negative return on equity of 67.69%. The company had revenue of $3.09 million for the quarter, compared to analyst estimates of $5.07 million.

Several research firms recently commented on TBPH. BidaskClub raised shares of Theravance Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Needham & Company LLC boosted their price target on shares of Theravance Biopharma from $40.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, May 11th. Leerink Swann set a $47.00 price target on shares of Theravance Biopharma and gave the company a “buy” rating in a report on Wednesday, May 10th. ValuEngine upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Cantor Fitzgerald set a $55.00 price target on shares of Theravance Biopharma and gave the company a “buy” rating in a report on Wednesday, July 19th. Four equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $41.13.

ILLEGAL ACTIVITY NOTICE: “” was published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/2796935/2796935.html.

Several large investors have recently added to or reduced their stakes in TBPH. Teachers Advisors LLC raised its stake in Theravance Biopharma by 15.2% in the first quarter. Teachers Advisors LLC now owns 80,113 shares of the biopharmaceutical company’s stock worth $2,950,000 after buying an additional 10,550 shares in the last quarter. Harvest Management LLC purchased a new stake in Theravance Biopharma during the first quarter worth about $228,000. Principal Financial Group Inc. purchased a new stake in Theravance Biopharma during the first quarter worth about $420,000. American International Group Inc. raised its stake in Theravance Biopharma by 16.4% in the first quarter. American International Group Inc. now owns 24,276 shares of the biopharmaceutical company’s stock worth $894,000 after buying an additional 3,417 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp raised its stake in Theravance Biopharma by 31.9% in the first quarter. OMERS ADMINISTRATION Corp now owns 9,500 shares of the biopharmaceutical company’s stock worth $350,000 after buying an additional 2,300 shares in the last quarter. Institutional investors and hedge funds own 84.10% of the company’s stock.

Shares of Theravance Biopharma (NASDAQ:TBPH) opened at 23.88 on Thursday. The firm’s market capitalization is $1.27 billion. The stock’s 50 day moving average is $36.84 and its 200-day moving average is $35.54. Theravance Biopharma has a 52-week low of $23.15 and a 52-week high of $43.44.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.